Helmut Salih

Helmut Salih is a Professor of Translational Immunology at the University of Tübingen and serves as the Medical Director of the Clinical Cooperation Unit for Translational Immunology within the German Consortium for Translational Cancer Research (DKTK) at the German Cancer Research Center (DKFZ). His work bridges clinical hematology/oncology with cutting-edge immunotherapy research, focusing on leukemia and solid tumors.

• Institution: University of Tübingen
• Department: Translational Immunology
• Key Collaborations: DKTK, DKFZ

Research Focus: Dr. Salih's research spans translational immunology, cancer immunotherapy, and targeted treatments for hematologic malignancies. His work includes clinical trials for AML and fibrolamellar hepatocellular carcinoma, emphasizing T cell-based interventions and MRD monitoring.

Selected Publications: His recent studies address clonal evolution in AML under midostaurin, CD276 targeting in breast cancer, and peptide vaccines for SARS-CoV-2. These reflect his expertise in antigen-specific therapies and immune surveillance mechanisms.

Leadership Roles: As Head of the Clinical Cooperation Unit and Medical Director, he integrates academic research with clinical application, particularly in leukemia and immunotherapy. His affiliations with DKTK and DKFZ highlight his role in translational cancer research networks.